2006
Selective Serotonin Reuptake Inhibitors and Suicidality in Juveniles: Review of the Evidence and Implications for Clinical Practice
Rey JM, Martin A. Selective Serotonin Reuptake Inhibitors and Suicidality in Juveniles: Review of the Evidence and Implications for Clinical Practice. Child And Adolescent Psychiatric Clinics Of North America 2006, 15: 221-237. PMID: 16321732, DOI: 10.1016/j.chc.2005.08.012.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsSerotonin reuptake inhibitorsReuptake inhibitorsClinical practiceCareful clinical monitoringPharmacologic treatmentMedication complianceManic switchingSevere depressionClinical monitoringSuicidal behaviorBehavioral activationSuicidalityPersonal sufferingDepressionInhibitorsEvidenceNontreatment
2003
Low-Dose Fluvoxamine Treatment of Children and Adolescents with Pervasive Developmental Disorders: A Prospective, Open-Label Study
Martin A, Koenig K, Anderson GM, Scahill L. Low-Dose Fluvoxamine Treatment of Children and Adolescents with Pervasive Developmental Disorders: A Prospective, Open-Label Study. Journal Of Autism And Developmental Disorders 2003, 33: 77-85. PMID: 12708582, DOI: 10.1023/a:1022234605695.Peer-Reviewed Original ResearchConceptsPervasive developmental disorderSelective serotonin reuptake inhibitor responseOpen-label studyOpen-label trialLow-dose fluvoxamineDevelopmental disordersPremature discontinuationClinical responseFluvoxamine treatmentPartial respondersMean ageSerotonin levelsSelect childrenPubertal statusInhibitor responseBehavioral activationFluvoxamineChildrenFurther investigationDisordersTreatmentGender differencesAdolescentsSubjectsTolerability
1999
Open-Label Quetiapine in the Treatment of Children and Adolescents with Autistic Disorder
Martin A, Koenig K, Scahill L, Bregman J. Open-Label Quetiapine in the Treatment of Children and Adolescents with Autistic Disorder. Journal Of Child And Adolescent Psychopharmacology 1999, 9: 99-107. PMID: 10461820, DOI: 10.1089/cap.1999.9.99.Peer-Reviewed Original ResearchConceptsClinical Global Impression ScaleTreatment of childrenSide effectsAutistic disorderOpen-label trialShort-term safetyWeeks of treatmentGlobal Impression ScaleGlobal improvement itemSignificant side effectsSerious side effectsDSM-IV criteriaFurther dose increasesLack of responseMean ageImpression ScalePossible seizuresMale subjectsWeight gainBehavioral activationFourth weekQuetiapine fumarateDose increaseClinical populationsWeeks